Samsung Biologics

Samsung Biologics is a global contract development and manufacturing organization (CDMO) and a subsidiary of the Samsung Group. Established to capitalize on the growing biologics market, the company provides comprehensive services from cell line development to commercial-scale production for pharmaceutical and biotechnology firms worldwide. It has rapidly become one of the world's largest biologics manufacturing facilities by capacity, playing a significant role in the global biopharmaceutical supply chain.

History

The company was founded in 2011 as part of Samsung Group's strategic diversification into the biopharmaceutical industry. Its first plant, located in the Incheon Free Economic Zone, began operations in 2015, marking its entry into the competitive CDMO market. A pivotal moment in its early growth was securing a major manufacturing partnership with Bristol Myers Squibb in 2016. The company completed a successful initial public offering on the Korea Exchange in 2016, providing capital for aggressive expansion. Subsequent years saw the rapid construction of additional large-scale manufacturing plants, with Plant 3 becoming operational in 2018 and Plant 4 commencing production in 2022, solidifying its position as a capacity leader.

Facilities and operations

The company's primary manufacturing campus is situated in Songdo International Business District within the Incheon Free Economic Zone. This integrated site houses four major drug substance manufacturing plants, each designed with multi-purpose bioreactor trains ranging from small to very large scale. Plant 4 is notably one of the largest single biopharmaceutical factories in the world, featuring fully flexible stainless steel and single-use bioreactor systems. The campus also includes a dedicated antibody-drug conjugate facility and extensive laboratories for process development and quality control. All facilities are designed to comply with stringent international regulatory standards set by the FDA, the EMA, and other global health authorities.

Services and technologies

Its service portfolio encompasses the entire biopharmaceutical development lifecycle. This includes early-stage cell line development using proprietary platforms, process development, and analytical method development. The company offers extensive clinical and commercial manufacturing for monoclonal antibodies, fusion proteins, and other recombinant proteins. It has invested significantly in advanced technologies for antibody-drug conjugate manufacturing and has built capabilities in fill and finish operations. The firm utilizes state-of-the-art process automation and data analytics through its integrated digital plant platform to ensure operational excellence and consistent product quality.

Financial performance and market position

The company has demonstrated strong financial growth, with revenue consistently increasing year-over-year, driven by a large and growing order backlog from global clients. Its market capitalization makes it one of the most valuable entities on the Korea Exchange. As a pure-play CDMO, it competes directly with other industry leaders like Lonza, WuXi Biologics, and Fujifilm Diosynth Biotechnologies. The company's strategy focuses on capturing a significant share of the outsourced manufacturing market for biologics, which continues to grow as pharmaceutical companies increase their reliance on external partners.

Partnerships and collaborations

The company has established a broad network of strategic partnerships with major pharmaceutical and biotechnology companies. Early and significant collaborations include long-term manufacturing agreements with Bristol Myers Squibb and Roche. It has also formed partnerships with Pfizer, GlaxoSmithKline, and AstraZeneca for various therapeutic programs. During the COVID-19 pandemic, the company played a crucial role by providing manufacturing capacity for COVID-19 therapeutics and vaccine candidates. These alliances often involve multi-year contracts covering clinical supply and commercial production, underscoring its role as a trusted manufacturing partner in the global healthcare ecosystem.

Category:Biotechnology companies of South Korea Category:Companies listed on the Korea Exchange Category:Samsung Group Category:Companies based in Incheon